Abstract. Optimizing the use of recombinant human for more than a decade and its benefits are now being extended to pre-dialysis patients. Much has been erythropoietin (r-HuEPO) involves choosing an appropriate dose regimen and target haemoglobin level, learned about ways of optimizing the effects of r-HuEPO, while controlling the costs of treatment. addressing factors that inhibit response, and considering appropriate adjuvant therapy. Subcutaneous Much still remains to be learned. This paper reviews our current knowledge and highlights ongoing research administration of r-HuEPO two or three times weekly is optimal for most patients. Early detection and that may allow us to use r-HuEPO even more effectively in future. Key issues include the optimum route treatment of iron deficiency is mandatory. Measurement of the percentage of hypochromic red and frequency of administration for r-HuEPO, the importance of intravenous (i.v.) iron supplementation, blood cells is a reliable marker of functional iron deficiency, and the treatment of choice is intravenous the correction of factors inhibiting a response to r-HuEPO, the potential role of adjuvant therapies, and iron. Other factors that can affect the response to r-HuEPO include blood loss (sometimes occult), the selection of an appropriate target haemoglobin value. These issues will be discussed in turn. infection, inflammation, hyperparathyroidism with marrow fibrosis, aluminium toxicity, vitamin B 12 /folate deficiency, haemolysis, bone marrow disorders,
Introduction
Dosage frequency for s.c. r-HuEPO [11, 15, 16 ] and even daily [16, 17] . From the practical point of view, the optimal dosage frequency for s.c. r-HuEPO in most patients is two or three times weekly. However, there is no doubt that, in certain patients, once weekly administration produces a satisfactory effect, though a slightly higher dose may be required. While there was some early evidence that once-daily administration might minimize the total dose requirement, this has not been substantiated, and it has not been taken up in routine clinical practice.
Iron monitoring and supplementation
Early detection and treatment of functional iron deficiency is mandatory in optimizing the use of r-HuEPO. Methods of iron monitoring and supplementation are described in full elsewhere in this supplement. Measurement of the percentage of hypochromic red Fig. 1 . Haemoglobin response to i.v. iron (iron dextran 250 mg blood cells is undoubtedly the most reliable method every two weeks), oral iron (ferrous sulphate 200 mg t.d.s.), or no currently available for detecting functional iron defi-iron in 37 patients treated with r-HuEPO [22] . ciency. It should be used along with the serum ferritin or transferrin saturation wherever possible. oral iron group required a slight increase in r-HuEPO In functional iron deficiency occurring as a result of dose to maintain their starting haematocrit, whereas r-HuEPO treatment, iron must be administered by the those receiving i.v. iron showed a striking reduction in i.v. route in order to have an immediate and sustained dose requirement during the first two months of the impact on erythropoiesis. Aggressive i.v. iron therapy study. This lower dose requirement was then mainis increasingly recognized as a means of enhancing the tained for a further two months to the end of the response to r-HuEPO, with obvious implications for period of follow-up. an improved cost5benefit ratio. Evidence from 10 studies conducted since 1992, including a total of more than 450 patients, shows that intensive i.v. iron
Other factors affecting the response to r-HuEPO supplementation allows a reduction in dose of 19-70% [9, [18] [19] [20] [21] [22] [23] [24] [25] [26] .
The benefits of using the i.v. route are demonstrated Although iron deficiency is probably the most imporby a randomized controlled study by Macdougall et al. tant factor affecting the response to r-HuEPO in most in 37 patients. Of these, 12 received i.v. iron dextran patients, blood loss (often occult), infection and (250 mg every 2 weeks), 13 received oral ferrous inflammation are also important. Factors affecting a sulphate, 200 mg t.d.s., and 12 received no iron [22] . minority of patients include hyperparathyroidism with The starting haemoglobin was< 8.5 g/dl, and ferritin marrow fibrosis, aluminium toxicity, vitamin B 12 /folate 100-800 mg/l. Over the 16 weeks of the trial, the group deficiency, haemolysis, bone marrow disorders, haemoreceiving i.v. iron had by far the best response globinopathies, under-dialysis and carnitine deficiency. (Figure 1 ). The responses of the no-iron and oral iron Whether angiotensin-converting enzyme (ACE) inhibgroups were remarkably similar, indicating that oral itors affect the response to r-HuEPO is still a matter iron conferred no benefit over no-iron administration. of controversy. This may be partly due to non-compliance, as oral iron is poorly tolerated. In this study, the mean ferritin
Role of adjuvant therapy
level on entry was around 300 mg/l (i.e. patients were initially not iron-deficient). In patients receiving i.v. iron, ferritin remained at around 300 mg/l throughout In addition to i.v. iron supplementation, a number of the study. In contrast, in the no-iron and oral iron other measures have been examined as a means of groups ferritin levels fell. The dose of r-HuEPO optimizing the effect of r-HuEPO, as described below. required was significantly lower in the i.v. iron group compared with the no-iron group.
Intravenous ascorbic acid The findings of this study were similar to those of Fishbane et al., who studied 52 patients in whom Although very limited data are available, ascorbic acid is a promising adjuvant therapy in patients with iron anaemia had already been partially corrected with r-HuEPO [21] . In this study, patients randomized to overload showing a suboptimal response. At present there is only one published paper on the role of i.v. oral iron showed no further change in haematocrit, whereas those who received aggressive i.v. iron ascorbic acid in patients on r-HuEPO: an uncontrolled study by Gastaldello et al.
[27] in four haemodialysis supplementation showed a significant increase. The
Folic acid
Aggressive treatment with oral folic acid (10 mg/day) has been shown to improve the response to r-HuEPO, but only in patients with a high mean cell volume [29] . This effect occurred even when the baseline folic acid levels were normal.
Vitamin D
A recent study by Albitar et al. found an enhanced response to r-HuEPO when vitamin D was given as an adjuvant therapy to patients with mild-to-moderate hyperparathyroidism [30] . However, it is not clear whether this was a specific effect of vitamin D, or hyperparathyroidism. Suppression of parathyroid hormone (PTH ) did occur in this study. However, a previous study showed a benefit of vitamin D in patients. All these patients were iron-overloaded, with r-HuEPO-treated dialysis patients, even though there very high serum ferritin levels-almost 1000 mg/l. They was no effect on PTH [31] . It therefore remains were given high-dose ascorbic acid: 500 mg i.v. after debatable whether vitamin D has a specific effect on each haemodialysis session, three times weekly. The erythropoiesis, or whether it acts via suppression of haemoglobin rose after each period of ascorbic acid hyperparathyroidism. The importance of hyperparaadministration, then fell again when ascorbic acid was thyroidism in inhibiting the response to r-HuEPO is stopped ( Figure 2) . itself controversial.
-Carnitine
Cytokines and growth factors A recent placebo-controlled study by Labonia et al. So far, the only evidence for the potential role of treated 13 dialysis patients (already receiving cytokines and growth factors as adjuvant therapies r-HuEPO) with high doses of -carnitine, 1000 mg i.v. comes from animal studies. In a study in mice by Brox after every dialysis session for 6 months. The -et al., insulin-like growth factor-1 (IGF-1) reduced the carnitine-treated group showed a 38% reduction in threshold concentration of r-HuEPO required to r-HuEPO requirements compared with the placebo increase haemoglobin levels [32] . A study by group (11 patients) (P<0.02) [28] . This difference was Macdougall et al. [33] found that s.c. interleukin-3 due to a marked response in about half the patients: (IL-3) augmented the effect of r-HuEPO in uraemic seven patients appeared to show a reduction in anaemic rabbits. In these 5/6 nephrectomized rabbits, r-HuEPO dose requirements while the remaining six r-HuEPO alone at a dose of 50 IU/kg, three times did not ( Figure 3) . weekly s.c., produced an increase in haemoglobin levels, which was enhanced by co-administration of IL-3. This is what would be expected, given the known action of IL-3 in mobilizing erythroid progenitors from the stem cell pool.
Target haemoglobin and long-term morbidity and mortality
Optimizing the response to r-HuEPO is not only a matter of enhancing the response to currently used doses, but of setting a target haemoglobin level that will achieve the greatest possible benefits for our patients. The current practice is to aim for a target haemoglobin of 10-12 g/dl. There is, however, much controversy over whether this level should be higher. There is already evidence that increasing the target haemoglobin to a near-normal level improves exercise capacity. It has been hypothesized that it may, by reducing both cardiac ischaemia and left ventricular hypertrophy, improve the high cardiovascular morbid- Fig. 3 . Effect of 6 months of treatment with -carnitine or placebo on r-HuEPO dose requirements [28] .
ity and mortality associated with end-stage renal fail-ure. Three multicentre studies were set up to investigate Whether these substances, or erythropoietin gene therapy, will ever become a clinical reality, only time this issue: the US Amgen study in high-risk cardiac patients, and ongoing studies in Scandinavia and will tell. In the meantime, i.v. iron and perhaps other adjuvant therapies offer a real possibility of maximizing Canada.
the potential of the treatment we have already.
US Amgen study
The Amgen study, which is due to be published shortly, References had recruited 1265 patients at the time it was aborted (not significant). However, it is important to note that 2. Bommer J, Barth H-P, Zeier M et al. Correction of anaemia in patients on continuous ambulatory months, cardiac and other endpoints will be examined, peritoneal dialysis with subcutaneous recombinant erythropoietin twice a week: a long-term study. Clin Nephrol 1991; 35:
